Structures by: Hulme A. T.
Total: 35
5-Ethyluracil
C6H8N2O2
New Journal of Chemistry (2008) 32, 10 1761
a=3.9193(18)Å b=5.754(3)Å c=14.366(7)Å
α=100.027(7)° β=96.109(7)° γ=92.374(8)°
5-Cyanouracil
C5H3N3O2
New Journal of Chemistry (2008) 32, 10 1761
a=9.0098(18)Å b=6.6035(13)Å c=9.1805(18)Å
α=90.00° β=98.124(3)° γ=90.00°
5-Chlorouracil
C4H3ClN2O2
New Journal of Chemistry (2008) 32, 10 1761
a=8.4393(10)Å b=6.8412(8)Å c=9.3679(12)Å
α=90.00° β=104.201(2)° γ=90.00°
5-Bromouracil
C4H3BrN2O2
New Journal of Chemistry (2008) 32, 10 1761
a=8.5680(11)Å b=6.8823(9)Å c=9.5715(12)Å
α=90.00° β=103.440(2)° γ=90.00°
C4 H3 F N2 O2, C7 H5 N
C11H8FN3O2
New Journal of Chemistry (2008) 32, 10 1761
a=7.0460(7)Å b=24.035(2)Å c=6.8640(7)Å
α=90.00° β=116.554(2)° γ=90.00°
C4 H3 F N2 O2 , C H3 N O
C5H6FN3O3
New Journal of Chemistry (2008) 32, 10 1761
a=6.827(4)Å b=6.111(3)Å c=8.424(4)Å
α=90.00° β=90.313(8)° γ=90.00°
2(C19H30O2),H2O
2(C19H30O2),H2O
CrystEngComm (2006) 8, 4 309
a=7.4288(8)Å b=10.2892(11)Å c=22.174(2)Å
α=90.00° β=97.553(2)° γ=90.00°
Androsterone
C19H30O2
CrystEngComm (2006) 8, 4 309
a=9.4045(9)Å b=7.9586(8)Å c=11.6746(12)Å
α=90.00° β=111.274(2)° γ=90.00°
Racemic progesterone
C21H30O2
Chemical Communications (2006) 47
a=10.9219(17)Å b=7.4400(12)Å c=21.034(3)Å
α=90.00° β=93.362(3)° γ=90.00°
4-Amino-5-fluoropyrimidin-2(1H)-one--2-amino-5-fluoropyrimidin-4(3H)-one--water (1/1/1)
C4H4FN3O,C4H4FN3O,H2O
Acta Crystallographica Section E (2005) 61, 7 o2112-o2113
a=5.4122(16)Å b=8.447(2)Å c=12.083(4)Å
α=89.454(5)° β=85.718(5)° γ=77.096(4)°
3-Azabicyclo[3.3.1]nonane-2,4-dione
C8H11N1O2
Acta Crystallographica Section E (2006) 62, 7 o3046-o3048
a=7.67102(18)Å b=10.5483(2)Å c=18.8867(4)Å
α=90° β=95.5800(12)° γ=90°
4,4,4-trifluoro-trans-2-butenoic acid
C4H3F3O2
Acta Crystallographica Section E (2003) 59, 5 o665-o666
a=10.8280(2)Å b=9.8064(2)Å c=10.1768(2)Å
α=90° β=94.3070(10)° γ=90°
5-Fluorouracil Dimethylformamide (2/1)
2C4H3FN2O2,C3H7NO
Acta Crystallographica Section E (2004) 60, 10 o1783-o1785
a=14.7361(18)Å b=5.8693(7)Å c=16.397(2)Å
α=90.00° β=100.524(2)° γ=90.00°
5-Fluorouracil 1,4-dioxane (4/1)
C4H8O2,4C4H3FN2O2
Acta Crystallographica Section E (2004) 60, 10 o1781-o1782
a=7.0847(11)Å b=8.4733(13)Å c=10.2291(15)Å
α=98.128(3)° β=96.913(3)° γ=99.785(3)°
5-Fluorouracil Dimethylsulfoxide (1/1)
C2H6OS,C4H3FN2O2
Acta Crystallographica Section E (2004) 60, 10 o1786-o1787
a=9.8831(10)Å b=10.8128(11)Å c=8.6842(9)Å
α=90.00° β=107.397(2)° γ=90.00°
5-fluorouracil--2,2,2-trifluoroethanol (1/1)
C4H3FN2O2,C2H3F3O
Acta Crystallographica Section E (2005) 61, 11 o3661-o3663
a=5.3976(6)Å b=6.7062(8)Å c=12.1098(14)Å
α=90° β=102.807(2)° γ=90°
Cyclohexane-1,3-dicarboximide, acetic acid (1/1)
C8H11NO2,C2H4O2
Acta Crystallographica Section E (2006) 62, 2 o545-o547
a=6.6224(7)Å b=7.3580(8)Å c=10.7995(12)Å
α=103.598(2)° β=93.378(2)° γ=97.272(2)°
Metaldehyde
C8H16O4
Acta Crystallographica Section E (2005) 61, 4 o857-o859
a=10.4974(10)Å b=10.4974(10)Å c=4.0967(7)Å
α=90.00° β=90.00° γ=90.00°
(R)-1-phenylethylammonium (R)-2-phenylbutyrate
C8H12N,C10H11O2
Acta Crystallographica Section E (2007) 63, 1 o247-o249
a=6.06200(10)Å b=16.7794(3)Å c=16.8881(4)Å
α=90° β=90° γ=90°
3-azabicyclo[3.3.1]nonane-2,4-dione 1-methylnaphthalene hemisolvate
C8H11NO2,0.5C11H10
Acta Crystallographica Section E (2006) 62, 9 o3752-o3754
a=15.02360(18)Å b=7.32295(12)Å c=22.5164(3)Å
α=90° β=106.0201(6)° γ=90°
(R)-1-phenylethylammonium (R)-2-phenylbutyrate
C8H12N,C10H11O2
Acta Crystallographica Section E (2007) 63, 1 o202-o204
a=11.88215(15)Å b=5.97647(8)Å c=13.07499(15)Å
α=90° β=113.5100(10)° γ=90°
5-fluorouracil--thymine
C4.48H4.45F0.52N2O2,C4.30H3.91F0.70N2O2
Acta Crystallographica Section C (2006) 62, 7 o412-o415
a=19.3785(15)Å b=5.9918(5)Å c=20.0293(15)Å
α=90.00° β=117.8130(10)° γ=90.00°
5-fluorouracil, thymine
C4.33H3.99F0.67N2O2,C4.24H3.73F0.76N2O2
Acta Crystallographica Section C (2006) 62, 7 o412-o415
a=19.235(3)Å b=5.9683(8)Å c=20.042(3)Å
α=90.00° β=118.216(2)° γ=90.00°
5-fluorouracil, thymine
C4.45H4.36F0.55N2O2,C4.31H3.94F0.69N2O2
Acta Crystallographica Section C (2006) 62, 7 o412-o415
a=19.856(11)Å b=5.946(3)Å c=20.073(11)Å
α=90.00° β=117.660(8)° γ=90.00°
5-fluorocytosine hemipentahydrate
2(C4H4FN3O),5(H2O)
Crystal Growth & Design (2006) 6, 2 481-487
a=12.2384(8)Å b=9.4254(6)Å c=13.8727(9)Å
α=90.00° β=111.3910(10)° γ=90.00°
5-fluorouracil
C4H3FN2O2
Journal of the American Chemical Society (2005)
a=8.6329(12)Å b=9.1560(13)Å c=12.5796(18)Å
α=99.119(2)° β=100.021(3)° γ=90.017(2)°
5-fluorouracil
C4H3FN2O2
Journal of the American Chemical Society (2005)
a=5.1540(16)Å b=15.001(5)Å c=6.654(2)Å
α=90.00° β=110.336(5)° γ=90.00°
5-fluorouracil form II
C4H3FN2O2
Journal of the American Chemical Society (2005)
a=5.0433(12)Å b=14.935(3)Å c=6.6049(15)Å
α=90.00° β=108.884(4)° γ=90.00°
5-fluorocytosine 2,2,2-trifluoroethanol
C4H4FN3O,C2H3F3O
Crystal Growth & Design (2006) 6, 2 481-487
a=11.1490(9)Å b=9.5914(8)Å c=8.5221(7)Å
α=90.00° β=108.1390(10)° γ=90.00°
5-fluorocytosine monohydrate
C4H4FN3O,H2O
Crystal Growth & Design (2006) 6, 2 481-487
a=7.3871(6)Å b=9.3940(8)Å c=17.5787(15)Å
α=90.00° β=98.608(2)° γ=90.00°
5-fluorocytosine monohydrate II
C4H4FN3O,H20
Crystal Growth & Design (2006) 6, 2 481-487
a=4.1026(5)Å b=8.2731(10)Å c=9.9191(12)Å
α=110.036(2)° β=100.460(2)° γ=96.710(2)°
5-fluorocytosine Form II
C4H4FN3O
Crystal Growth & Design (2006) 6, 2 481-487
a=4.0629(4)Å b=9.5211(9)Å c=12.7386(12)Å
α=90.00° β=92.986(2)° γ=90.00°
5-fluorocytosine hemipentahydrate
2(C4H4FN3O),5(H2O)
Crystal Growth & Design (2006) 6, 2 481-487
a=12.2384(8)Å b=9.4254(6)Å c=13.8727(9)Å
α=90.00° β=111.3910(10)° γ=90.00°
5-fluorocytosine methanol solvate 2/1
2(C4H4FN3O),CH4O
Crystal Growth & Design (2006) 6, 2 481-487
a=8.4486(9)Å b=9.2898(10)Å c=16.1042(18)Å
α=90.00° β=97.371(2)° γ=90.00°
5-fluorocytosine Form I
C4H4FN3O
Crystal Growth & Design (2006) 6, 2 481-487
a=6.6387(4)Å b=6.6387(4)Å c=23.471(3)Å
α=90.00° β=90.00° γ=90.00°